Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Applied Genetic Technologies Corp    AGTC

APPLIED GENETIC TECHNOLOGIES CORP (AGTC)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Applied Genetic Technologies Corp (NASDAQ:AGTC) reported earnings of ($0.18) per share missing Walls Streets expectations.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/13/2017 | 03:43pm CEST

Applied Genetic Technologies Corp (NASDAQ:AGTC) reported Q4 2017 earnings this Morning, coming in at ($0.18) per share, missing Wall Street’s estimates of $0.14 per Share. Revenue for the quarter came in at $8.30 million beating analyst estimates of $12.39 million

Analyst Coverage For Applied Genetic Technologies Corp (NASDAQ:AGTC)
These are 3 Hold Ratings, 6 Buy Ratings .
The current consensus rating for Applied Genetic Technologies Corp (NASDAQ:AGTC) is Buy (Score: 2.67) with a consensus target price of $14.63 , a potential (195.45% upside)Recent Insider Trading for Applied Genetic Technologies Corp (NASDAQ:AGTC)

  • On 11/16/2016Ivana Magovcevic, Director, bought 3,000 with an average share price of $9.63 per share and the total transaction amounting to $28,890.00.
  • On 11/1/2016 Jeffrey D Chulay, VP, sold 1,000 with an average share price of $7.05 per share and the total transaction amounting to $7,050.00.
  • On 9/22/2016 Mark S Shearman, Insider, bought 3,000 with an average share price of $8.87 per share and the total transaction amounting to $26,610.00.
  • On 9/20/2016 Stephen W Potter, Insider, bought 1,400 with an average share price of $8.89 per share and the total transaction amounting to $12,446.00.
  • On 9/19/2016 Lawrence E Bullock, CFO, bought 10,000 with an average share price of $8.75 per share and the total transaction amounting to $87,500.00.
  • On 2/23/2015 Plc Glaxosmithkline, Major Shareholder, sold 503,150 with an average share price of $22.00 per share and the total transaction amounting to $11,069,300.00.

    Recent Trading for Applied Genetic Technologies Corp (NASDAQ:AGTC) Shares of Applied Genetic Technologies Corp closed the previous trading session at with shares trading hands.

    The post Applied Genetic Technologies Corp (NASDAQ:AGTC) reported earnings of ($0.18) per share missing Walls Streets expectations. appeared first on Market Exclusive.

    © Market Exclusive 2017, source Market Exclusive

    share with twitter share with LinkedIn share with facebook
    share via e-mail
    0
    Latest news on APPLIED GENETIC TECHNOLOGI
    05/09APPLIED GENETIC TECHNOLOGIES CORPORA : (AGTC) Analysts See $-0.25 EPS
    AQ
    05/09APPLIED GENETIC TECHNOLOGIES : Fiscal 3Q Earnings Snapshot
    AQ
    05/08APPLIED GENETIC TECHNOLOGIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL..
    AQ
    05/08AGTC Announces Financial Results and Business Update for the Quarter Ended Ma..
    GL
    05/08APPLIED GENETIC TECHNOLOGIES CORP : Results of Operations and Financial Conditio..
    AQ
    04/30AGTC to Host Third Quarter Financial Results Conference Call and Webcast on M..
    GL
    04/18AGTC Doses First Patient in Phase 1/2 Clinical Study of Gene Therapy for the ..
    GL
    04/10AGTC Announces Completion of Enrollment of Phase 1 / 2 Clinical Study of Inve..
    GL
    03/02APPLIED GENETIC TECHNOLOGIES CORP : Submission of Matters to a Vote of Security ..
    AQ
    02/14APPLIED GENETIC TECHNOLOGIES : AGTC Announces Sue Washer, CEO, Elected to Biotec..
    PU
    More news
    News from SeekingAlpha
    05/18MeiraGTx Aims For $86 Million U.S. IPO 
    05/11Applied Genetic Technologies' (AGTC) CEO Sue Washer on Q3 2018 Results - Earn.. 
    05/08Applied Genetic misses by $0.04, misses on revenue 
    05/07Notable earnings after Tuesday?s close 
    02/10Finding Biotech Value In All-Time Highs 
    Financials ($)
    Sales 2018 26,2 M
    EBIT 2018 -20,5 M
    Net income 2018 -18,1 M
    Debt 2018 -
    Yield 2018 -
    P/E ratio 2018 -
    P/E ratio 2019
    Capi. / Sales 2018 3,19x
    Capi. / Sales 2019 3,15x
    Capitalization 83,8 M
    Chart APPLIED GENETIC TECHNOLOGI
    Duration : Period :
    Applied Genetic Technologi Technical Analysis Chart | AGTC | US03820J1007 | 4-Traders
    Technical analysis trends APPLIED GENETIC TECHNOLOGI
    Short TermMid-TermLong Term
    TrendsBearishNeutralBullish
    Income Statement Evolution
    Consensus
    Sell
    Buy
    Mean consensus OUTPERFORM
    Number of Analysts 6
    Average target price 8,00 $
    Spread / Average Target 73%
    EPS Revisions
    Managers
    NameTitle
    Susan B. Washer President, Chief Executive Officer & Director
    William A. Sullivan Chief Financial Officer
    Mark S. Shearman Chief Scientific Officer & Vice President
    Matthew Feinsod Chief Medical Officer
    James Rosen Independent Director
    Sector and Competitors
    1st jan.Capitalization (M$)
    APPLIED GENETIC TECHNOLOGIES CORP28.47%84
    GILEAD SCIENCES-5.60%87 612
    VERTEX PHARMACEUTICALS4.75%40 136
    REGENERON PHARMACEUTICALS-21.64%31 122
    GENMAB15.89%11 430
    BEIGENE LTD (ADR)94.13%10 161